Pharmacological strategies for kidney function preservation: are there differences by ethnicity?

Area of Science:

• Nephrology
• Public Health
• Cardiovascular Medicine

Background:

• Rising prevalence of chronic kidney disease (CKD) across all ethnic groups.
• Increased incidence linked to obesity, diabetes mellitus, metabolic syndrome, and poor cardiovascular-renal risk factor control, particularly in ethnic minorities.
• Significant negative impact on patient quality of life and substantial financial burden on healthcare systems.

Purpose of the Study:

• To devise strategies for preventing kidney disease and delaying its progression.
• To highlight the importance of risk factor management in CKD.
• To address the underrepresentation of ethnic minorities in clinical trials and apply existing evidence to these populations.

Main Methods:

• Review of proven pharmacological interventions for blood pressure control (<130/80 mm Hg) and glycemic control (HbA1c <7%).
• Emphasis on reducing urinary protein excretion.
• Analysis of clinical trial data, including recent trials in Black populations, to inform strategies for kidney function preservation.

Main Results:

• Pharmacological targeting of the renin-angiotensin-aldosterone system (RAAS) with ACE inhibitors and ARBs preserves kidney function, especially with proteinuria.
• Reversible risk factors for CKD are similar across ethnic groups.
• Effective management of risk factors like hypertension and diabetes is crucial for all populations, including ethnic minorities.

Conclusions:

• Applying existing evidence to ethnic minorities with CKD is logical due to universal risk factors and poor control.
• Efficient use of proven strategies can reduce the excess burden of CKD and end-stage renal disease (ESRD) in ethnic minorities.
• Public health approaches addressing obesity and diabetes are essential to complement medical strategies in combating the CKD epidemic.